En Es
Categories

Industry News

Samsung NeuroLogica to Operate Digital Radiography and Ultrasound Business Under New Brand

By Medimaging International staff writers
08 Mar 2022

Image: Boston Imaging to commercialize Samsung DR and US imaging products in USA (Photo courtesy of Boston Imaging)

NeuroLogica Corp., the U.S. healthcare subsidiary of Samsung (Suwon-si, South Korea), has announced that the company’s digital radiography and ultrasound (DR & US) business will operate under a new brand called Boston Imaging (Danvers, MA, USA).


Boston Imaging markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. Boston Imaging is the US headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. Boston Imaging’s growing portfolio of advanced medical technologies is used in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction and increase workflow efficiency.


“This is a momentous day for the company, as it will allow us even greater focus on our core expertise, providing the U.S. market with innovative, best-in-class Digital Radiography and Ultrasound imaging devices with Samsung healthcare technology at the core,” said David Legg, Vice President, Ultrasound and Digital Radiography, Boston Imaging. “As we continue gaining market leadership, this change will also allow Boston Imaging to have a more dedicated focus for growing the business.”


“The Samsung name is synonymous with industry-leading imaging technology,” said Legg. “In the healthcare imaging market, Samsung is the only true technology company that is now in healthcare imaging, while competitors come from industrial roots that have pursued healthcare as an add-on business. This company specializes in delivering exquisite imaging results.”


“Our new brand, Boston Imaging, reinforces the strength of our legacy and signals the potential of our future,” added Legg. “Our past advancements and achievements within the two modalities include the current introduction of innovative products such as the V8 Ultrasound system and artificial intelligence solutions, like Auto Lung Nodule Detection (ALND) tool, in Digital Radiography.”


“Boston Imaging’s team mission is improving patient care by developing outstanding, customer-centric imaging solutions quickly and with passion. We remain committed to our vision of making the world a healthier place by empowering clinicians to diagnose their patients more confidently, quickly and cost-effectively,” said Legg. “We will continue to maintain our normal business operations and operating structure. The legal entity and name of the company remains NeuroLogica Corp. We will be Doing Business As (DBA), Boston Imaging. The mobile computed tomography (CT) business will continue to operate under the existing company name, NeuroLogica.”


Related Links:
Samsung 
Boston Imaging 



E-mail Print
FaceBook Twitter Google+ Linked in

Samsung

Develops, manufactures, and markets diagnostic products and solutions for IVD and point-of-care applications
More info

More articles about Samsung

14 Oct 2022
Samsung Splits Ultrasound Business into Two Separate Divisions
Samsung has announced that the company will be adopting a segmented approach of both the Women’s Health and Radiology ultrasound business units to drive faster technology adoption through a greater understanding of the specific patient population and clinical markets served.
Read More

Additional news

23 Nov 2022
Global Visualization Instruments for MIS Market Driven by Increasing Demand for Endoscopy Procedures
The increasing demand for visualization systems for complex surgical procedures, growing demand for minimally invasive surgeries, and rising prevalence of chronic diseases are expected to help the global visualization instruments for minimally invasive surgery (MIS) market register a CAGR of 7.2% between 2022 and 2031 and reach a value of USD 21 billion by 2031.
Read More
11 Nov 2022
Global Diagnostic ECG Market Driven by Increased Incidence of Cardiac Diseases
The rising prevalence of such chronic conditions is necessitating the need for diagnosis and treatment in order to keep track of the patient's daily medical condition and maintain medical records. This, coupled with rising hospitalization of the older population for the treatment of cardiac diseases, has increased the need for electrocardiograph (ECG) diagnosis.
Read More
11 Nov 2022
Radcal to Supply Quality Assurance X-Ray Testing Equipment to West Physics
Radcal Corporation (Monrovia, CA, USA), a leading manufacturer of diagnostic X-ray quality assurance (QA) meters, has reached an agreement with West Physics (Atlanta, GA, USA), one of the largest and most successful Medical Physics groups in the U.S., to supply QA X-ray testing equipment.
Read More
09 Nov 2022
Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling
Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining panels, tissue staining, and imaging and analysis services.
Read More
08 Nov 2022
Global Infusion Pumps Market Driven by Increasing Incidence of Chronic Diseases
Rising demand for ambulatory infusion pumps in home care, increasing incidence of chronic diseases along with a rapid growth of the geriatric population, and growing number of surgical procedures being performed, are driving the growth of the global infusion pumps market. As a result, the market is projected to register a CAGR of 7% from USD 14.7 billion in 2022 to USD 20.5 billion by 2027.
Read More
07 Nov 2022
Mast Group Enters into Multi-Country Distribution Agreement for Nanomix's eLab System
Mast Group Limited (Liverpool, UK) and Nanomix (Emeryville, CA, USA) have entered into a multi-region distribution agreement wherein Mast will market and distribute the Nan?mix eLab system in the UK, Germany, France, Ireland and South Africa.
Read More
07 Nov 2022
AI-Enabled Diagnostic Testing Could Become More Accurate and Reliable than Current Tests
An expanded collaboration between two industry leaders will pave the way for the development of AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.
Read More
01 Nov 2022
Global Infectious Respiratory Disease Diagnostics Market Driven by New Multiplex PCR Tests and POC Products
The global infectious respiratory disease diagnostics market size is expected to reach USD 43.6 billion by 2030, driven by an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & non-profit organizations to introduce novel & innovative products to address the growing demand.
Read More
01 Nov 2022
Johnson & Johnson to Acquire Cardiovascular Technology Company Abiomed in USD 16.6 Billion Deal
Johnson & Johnson (New Brunswick, N.J., USA) has entered into a definitive agreement to acquire all outstanding shares of Abiomed, Inc. (Danvers, MA, USA) in a deal valued at approximately USD 16.6 billion which includes cash acquired.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions